C-JTPWHCW Biologics
fusion immunotherapeutics, cytokine platforms, immune-cell rebalancing
modulatingimmunotherapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JTPW
C-JTPWC-JTPWfusion immunotherapeutics, cytokine platforms, immune-cell rebalancing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This week's top insider trade: CHIDSEY JOHN bought $2,504,610 of $NCLH. Here are the highest-scoring insider trades from May 25-29, 2026. This Week's Top Insider Trades (May 25-29, 2026): 1. $NCLH -- CHIDSEY JOHN (President and CEO) BOUGHT 153,000 shares at $16 ($2,504,610) | Score: 83/100 President and CEO CHIDSEY JOHN purchased $2,504,610 of NCLH (153,000 shares at $16.37). This represents a 16% increase in their position. The stock was trading 40% below its 52-week high. 2. $HLNE -- Rogers Hartley R. (Executive Co-Chairman) BOUGHT 47,025 shares at $90 ($4,231,780) | Score: 81/100 Executive Co-Chairman Rogers Hartley R. purchased $4,231,780 of HLNE (47,025 shares at $89.99). The stock was trading 50% below its 52-week high. 3. $HCWB -- Wong Hing C (Chief Executive Officer) BOUGHT 113,879 shares at $1 ($160,000) | Score: 81/100 Chief Executive Officer Wong Hing C purchased $160,000 of HCWB (113,879 shares at $1.41). This represents a 23% increase in their position. The st
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, discusses the Company’s lead product candidate, known as HCW11-040, which is the Company’s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor.
Dr. Peter Rhode, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics discusses the Company’s recent news announcing its second-generation T-Cell Engager program. The Company has joined a small group of innovative biotechnology companies who have discovered new compounds that overcome resistance mechanisms and improve the ability to treat solid tumors.
HCW Biologics Inc. Stock Prediction and Forecast [HCWB] HCW Biologics Inc. price prediction was made for Tuesday, August 26, 2025 ▪️ Check the most recent HCWB analysis at: https://stockinvest.us/stock/HCWB ❓ How to Buy HCWB stock? https://stockinvest.us/how-to-buy-hcw-biologics-stock We go over the HCWB Inc. stock and give our stock price prediction (HCWB). Our HCWB stock price analysis and stock price forecast on HCWB for Tuesday, August 26, 2025 HCW Biologics Inc. Stock Analysis - HCWB Stock Price Prediction for Tuesday, August 26, 2025 HCWB STOCK: THIS IS A HCWB STOCK PRICE PREDICTION, HCWB STOCK PRICE ANALYSIS, AND A HCWB STOCK PRICE FORECAST VIDEO. 🚀 GET THE 30% PREMIUM DEAL TODAY + 14-DAY TRIAL https://stockinvest.us/order/youtube-channel 🚀 💰💰BECOME AN AFFILIATE AND EARN MONEY WITH US💰💰 https://stockinvest.us/affiliates?ref=YT ▪️ Join us: X: https://twitter.com/StockInvestUS Stocktwits: https://stocktwits.com/StockInvest_us Reddit: https://www.reddi
This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations at HCW Biologics, a company specializing in immunotherapies for age-related diseases discusses their research in "inflammaging", a field of drug research that develops treatments that address the relationship between the subtle but chronic low-grade inflammation characteristics of advancing age and a host of age-related disorders such as cancer, coronary artery disease, diabetes, fibrotic diseases and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. They are expecting to begin a Phase 1 trial for pancreatic cancer as a "stepping stone" towards developing treatment for these other diseases. #HCWBiologics #Inflammaging Dr. Rhode has more than two decades of biomedical research, drug discovery and development experience. He most recently served as the Vice President/Senior Vice President of Research and Development at Altor BioScience since its inception in 2002. Dr. Rhode made s
HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering July 19, 2021 | 2 min read Twitter LinkedIn Facebook Email Print HCW Biologics Inc. today announced the pricing of an underwritten initial public offering of 7,000,000 shares of common stock at a public offering price … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune February 13, 2026 | 10 min read Twitter LinkedIn Facebook Email Print HCW Biologics receiving cash fee and co-founder shares in Trimmune valued at $7.0 million Trimmune will hold exclusive wor … rcialization of the licensed molecules. Trimmune is backed by the CITIC Medical Fund (“CITIC”), a multi-billion-dollar investment fund focused on innovative companies primarily targeting pharmaceuticals, biotechnology, medical devices, and diagnostics, and TigerYeah Capital Fund of TigerMed (“TigerMed”), a global leading Contract Research Organization. Trimmune is led by a team with an impressive track record for success in the development and commercialization of … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter March 2, 2026 | 4 min read Twitter LinkedIn Facebook Email Print MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-s … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic March 17, 2026 | 5 min read Twitter LinkedIn Facebook Email Print Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in … gene/cell therapies, and the Company. Trimmune investors include CITIC Medical Fund, a multi-billion-dollar investment fund focused on innovative companies primarily targeting pharmaceuticals, biotechnology, medical devices, and diagnostics, and TigerYeah Capital Fund of TigerMed, a global leading Contract Research Organization. Trimmune is led by a team with an impressive track record for success in the development and commercialization of innovative drugs that treat diseas … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules May 21, 2026 | 4 min read Twitter LinkedIn Facebook Email Print MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCW … on rights agreement with the Investors, pursuant to which the Company agreed to submit to the U.S. Securities and Exchange Commission (the “SEC”) an initial registration statement on Form S-1 within 60 days of the closing date covering the resale of the purchased shares and underlying shares for warrants, which may be issued from time to time upon the exercise of such warrants, and to use commercially reasonable efforts to cause the registration statement to be declared effec … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market August 25, 2025 | 7 min read Twitter LinkedIn Facebook Email Print Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developm … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors June 27, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease November 19, 2025 | 9 min read Twitter LinkedIn Facebook Email Print First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW930 … amsdell and Shimon Sakaguchi was recently acknowledged with the 2025 Nobel Prize in Physiology or Medicine for their groundbreaking work which was the discovery that T reg cells are the immune system’s security guards which prevent immune cells from attacking our own body. The Company believes that HCW9302 has the potential to activate and expand T reg cells in patients, reducing inflammation, while minimizing the risk of broad immunosuppression or unwanted side effects … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results April 1, 2026 | 16 min read Twitter LinkedIn Facebook Email Print MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stag … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial February 3, 2025 | 7 min read Twitter LinkedIn Facebook Email Print This study will evaluate HCW9302 in patients with moderate to severe alopecia areata MIRAMAR, Fla., Fe … today announced that it has received clearance of its Investigational New Drug Application (“IND”) from the U.S. Food and Drug Administration (“FDA”) to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in patients with moderate-to-severe alopecia areata, a common autoimmune disease in humans that currently has no curative FDA approved treatments. Alopecia areata causes sudden hair loss and can have a signi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Sear … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances March 16, 2026 | 10 min read Twitter LinkedIn Facebook Email Print Commercialization ready compound supports a new method of gen … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-VestFounder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Dru … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioMidwest HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-VestFounder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” March 24, 2022 | 4 min read Twitter LinkedIn Facebook Email Print HCW Biologics Inc. will participate in Maxim’s 2022 Virtual Growth Conference … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics’ Founder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business HCW Biologics’ Founder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year December 13, 2021 | 7 min read Twitter LinkedIn Facebook Email Print HCW Biologics Inc. announced today Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, was named the 2021 Weaver H. Gaines En … of the Year by BioFlorida. Presented annually at the BioFlorida Conference, the award recognizes an individual who has made extraordinary contributions to the growth of life sciences in the leadership of a company or institution. This marks the second time Dr. Wong has received the award; the first being in 2017. The award was presented at the BioFlorida Conference, which took place from December 8-10, 2021, in Orlando, Florida. BioFlorida represents 6,700 establishments and … h IT and bio-agriculture sectors. The Weaver H. Gaines Entrepreneur of the Year Award is named in honor of Weaver Gaines, one of the founding directors of BioFlorida. “We are pleased to once again present Dr. Wong with the Entrepreneur of the Year award for his contributions to the Florida life sciences industry and his ongoing passion and commitment to developing transformative immunotherapies to lengthen the quality of life for those with cancer and other age-related diseas … nor and to be among the outstanding individuals who are past recipients of this award,” stated Dr. Wong. “This accolade is not mine alone but represents the hard work and commitment of the team at HCW Biologics, our research partners and the loyalty and commitment of our investors to a shared vision of harnessing groundbreaking research into the
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE S … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting November 8, 2022 | 6 min read Twitter LinkedIn Facebook Email Print HCW Biologics Inc. (the “Compan … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development September 17, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Lead product candidate will be advanced to late IND-enabling stud … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting November 10, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engage … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Deals J&J glows with $1B buyout of Firefly and its degrader platform tech June 8, 2026 · 1 min read · Gabrielle Masson BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovativ … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer October 17, 2025 | 4 min read Twitter LinkedIn Facebook Email Print Company poster presentations will debut research data of three lead drug candidates constructed with Company’s no … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results May 16, 2025 | 12 min read Twitter LinkedIn Facebook Email Print MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical compa … the terms of the WY Biotech exclusive worldwide licensing agreement to use and apply HCW11-006 for in vivo applications. HCW11-006 is a preclinical drug built with our second-generation discovery and development platform -- the TRBC platform. WY Biotech has 30-days due diligence to study this report, after which the Company expects to recognize revenue for a $7.0 million upfront licensing fee. Financing Transactions On May 15, 2025, the Company completed a $5.0 million … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Poster Presentation at AACR Annual Meeting 2023 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search HCW Biologics Poster Presentation at AACR Annual Meeting 2023 April 13, 2023 | 4 min read Twitter LinkedIn Facebook Email Print HCW Biologics Inc. today announced that data for the mechanism underlying HCW9218 against solid tumors will be presented at the 2023 Annual Meeting of the American Association for Cancer Resear … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022 May 23, 2022 | 3 min read Twitter LinkedIn Facebook Email Print HCW Biologics Inc. announced today that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will give a corporate presentation on May 25, 2022 at the … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Obesity ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction June 8, 2026 · 2 min read · Tristan Manalac BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunitie … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Unveils Next-Gen T-Cell Engager for Solid Tumors | HCWB Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto
HCW Biologics Advances Lead Product Candidate HCW11-040 to Late Stage IND-Enabling Studies for Solid Tumor Treatment | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On HCWB Stock Enter your email to receive free breaking news alerts and insights related to HCWB. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Donald Trump Stock Trades Election Fun … actions, check out Quiver Quantitative's insider trading dashboard. $HCWB Hedge Fund Activity We have seen 0 institutional investors add shares of $HCWB stock to their portfolio, and 11 decrease their positions in their most recent quarter. Here are some of the largest recent moves: VANGUARD GROUP INC removed 6,079 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $24,103 GEODE CAPITAL MANAGEMENT, LLC removed 5,924 shares (-100.0%) from their portfolio in Q2
HCW Biologics Inc. (HCWB) Leadership & Management Team Analysis - Simply Wall St Dashboard Portfolios Watchlist Community Discover Screener NOT FOR DISTRIBUTION HCW Biologics Inc. NasdaqCM:HCWB Stock Report Market Cap: US$9.2m Portfolio Add to Portfolio Holding More actions … Portfolio Add to Portfolio Holding … Company Overview 1 Valuation 2 Future Growth 3 Past Performance 4 Financial Health 5 Dividend 6 Management 7 Ownership Other Information Stock Community View Dividend HCW Biologics Management Management criteria checks 3/4 HCW Biologics' CEO is Hing Wong, appointed in Apr 2018 … r death, resignation, disqualification or removal; to ratify the appointment of Grant Thornton LLP as the independent registered public accounting firm of HCW Biologics Inc. for the fiscal year ending December 31, 2024; and to transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting. Show all updates Recent updates Announcement • Jun 02 HCW Biologics Inc. Receives Notice from Listing Qualifications Sta … the listing deficiencies and the Panel will, at that time, determine whether to grant the Company an exception to cure the deficiency. The Panel also required that Company provide prompt notification of any significant events that occur during the exception period that may affect the Company's compliance with Nasdaq requirements. If the Company regains compliance and satisfies the terms of the exception, the Panel intends to impose a Discretionary Panel Monitor on the Co … bling studies in the second half of 2027 and intends to immediately file an IND application to evaluate HCW11-040 in patients at a high risk of developing BPD. HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells. BPD causes abnormal lung development in premature infants that leads to long-term health problems that persist into adulthood as well as neurodevelopmental delays. BPD in neonates … rability of this tetra-valent T Cell Engager against human tumor cells. The IND application is projected to be filed in the first half of 2027. Announcement • Apr 24 HCW Biologics Inc. has filed a Follow-on Equity Offering in the amount of $5.6 million. HCW Biologics Inc. has filed a Follow-on Equity Offering in the amount of $5.6 million. Securi
EX-31.1 3 hcwb-ex31_1.htm EX-31.1 EX-31.1   Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Hing C. Wong, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of HCW Biologics Inc. for the quarter ended June 30, 2022; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance
HCW Biologics’ Founder and CEO Dr. Hing C. Wong Named --> Accessibility: Skip TopNav Consumer Products and Services News Automobiles and Parts News Food & Beverage News Home Goods & Construction News Leisure Goods News Media & Entertainment News Personal Care News Retail News Travel and Leisure News Energy News Alternative Energy News Oil Gas and Coal News Chemicals News Banks & Financial Services News Banking News Closed-End Investments News Finance and Credit Services News Investment Banking and Brokerage Services News Insurance News Real Estate & REITs News Healthcare Ne … ounder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year Award recognizes extraordinary contributions to the growth of life sciences December 13, 2021 07:31 ET | Source: HCW Biologics, Inc HCW Biologics, Inc MIRAMAR, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupti … of the Year by BioFlorida. Presented annually at the BioFlorida Conference, the award recognizes an individual who has made extraordinary contributions to the growth of life sciences in the leadership of a company or institution. This marks the second time Dr. Wong has received the award; the first being in 2017. The award was presented at the BioFlorida Conference, which took place from December 8-10, 2021, in Orlando, Florida. BioFlorida represents 6,700 establishments and … h IT and bio-agriculture sectors. The Weaver H. Gaines Entrepreneur of the Year Award is named in honor of Weaver Gaines, one of the founding directors of BioFlorida. “We are pleased to once again present Dr. Wong with the Entrepreneur of the Year award for his contributions to the Florida life sciences industry and his ongoing passion and commitment to developing transformative immunotherapies to lengthen the quality of life for those with cancer and other age-related diseas … nor and to be among the outstanding individuals who are past recipients of this award,” stated Dr. Wong. “This accolade is not mine alone but represents the hard work and commitment of the team at HCW Biologics, our research partners and the loyalty and commitment of our investors to a shared vision of harnessing groundbreaking research into the
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules – 1stOncology™: Cancer Intelligence Service 1stOncology™: Cancer Intelligence Service 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Skip to content 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers , signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology! Access F … on rights agreement with the Investors, pursuant to which the Company agreed to submit to the U.S. Securities and Exchange Commission (the "SEC") an initial registration statement on Form S-1 within 60 days of the closing date covering the resale of the purchased shares and underlying shares for warrants, which may be issued from time to time upon the exercise of such warrants, and to use commercially reasonable efforts to cause the registration statement to be decl
10-K 0001828673 FY December 31 false 0001828673 2022-08-26 0001828673 us-gaap:PropertyPlantAndEquipmentMember 2022-12-31 0001828673 hcwb:TreasuryNotesMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001828673 us-gaap:CommonStockMember hcwb:SeriesBRedeemablePreferredStockMember 2021-01-01 2021-12-31 0001828673 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001828673 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-12-31 0001828673 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001828673 us-gaap:CommonStockMember 2021-12-31 0001828673 us-gaap:OfficeEquipmentMember … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth compan … ctivities required to prepare an Investigational New Drug (“IND”) application in the first half of 2023. We expect to submit an IND application for a Phase 1b/2 clinical study to evaluate HCW9302 in an autoimmune disease to the FDA in the second half of 2023. Our ability to initiate a clinical trial to evaluate HCW9302 in an autoimmune disease depends on completion of our toxicology studies, preparation and submission of an IND, and obtaining clearance to procee … g activities are expected to be completed in the first half of 2023. We plan to submit an IND to the FDA for a Phase 1b/2 clinical trial to evaluate HCW9302 in an autoimmune disorder in the second half of 2023. Our ability to evaluate HCW9302 in a clinical trial depends on completion of our toxicology studies, preparation and submission of an IND, and obtaining clearance to proceed from the FDA. Our Approach We believe we have an innovative strategy to treat age-related disea … HCW9218 in pancreatic cancer in 2023. After determining the RP2D, we expect to submit an IND protocol amendment to the FDA for the Phase 2 portion of this clinical trial to include patients receiving HCW9218 as an adjunct to chemotherapy. In the Phase 2 dose expansion portion, we intend to enroll up to 40 patients at the RP2D with primary object
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Dr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors April 27, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor … ironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in first half of 2027 to seek authorization for clinical study in patients with pancreatic cancer Poster presented at the American Association of Cancer Research Annual Meeting 2026 MIRAMAR, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transforma … or solid tumors with particular focus on pancreatic and ovarian cancer. The IND application is projected to be filed in the first half of 2027.” The poster, entitled, “An innovative approach to improve bispecific T-cell engagers for solid tumor therapy,” was presented by Dr. Wong at the AACR Annual Meeting 2026. The poster is available on the Company’s investors’ website in the following link: https://investors.hcwbiologics.com/events/event-details/development-hcw11-018 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Christopher M Janney Resume/CV | Delaware State University, Biological Science, Adjunct Skip to main content Academia.edu uses cookies to personalize content, tailor ads and improve the user experience. By using our site, you agree to our collection of information through the use of cookies. To learn more, view our Privacy Policy . × Log In Sign Up Log In Sign Up more About Press Papers Terms Privacy Copyright We're Hiring! Help Center less Christopher M Janney - Curriculum Vitae Christopher M Janney Delaware State University, Biological Science, Adjunct Download Dr. Christopher M. J … and Development Differences Awards, Honors, Fellowships, & Grants NIH RISE Grant Fellow, Delaware State University 2017 - 2019 Professional Experience Research/Laboratory Associate Scientist, HCW Biologics, Inc. October 2021 - Focus on building and leading the neuroscience testing capabilities for Present aging-related neurodegenerative diseases with initial focus on Parkinson’s Disease and Alzheimer’s Disease. Built the behavior lab including allocating space, purchasin … ng PK/PD experiments including brain single cell suspension and flow cytometry. Grant writing and submission including to Michael J. Fox Foundation and NIH. Postdoctoral Scholar, Lab of Dr. Philip G. Haydon, Department of October 2020 - Neuroscience, Tufts University School of Medicine October 2021 Studying the relationship between glucose transporter 1 (GLUT1), astrocytes, sleep, aging, and dementia with a specific focus on Alzheimer’s Disease. Collaborating with a Molecular
0001193125-21-212790.txt : 20210712 0001193125-21-212790.hdr.sgml : 20210712 20210712131003 ACCESSION NUMBER: 0001193125-21-212790 CONFORMED SUBMISSION TYPE: FWP PUBLIC DOCUMENT COUNT: 13 FILED AS OF DATE: 20210712 DATE AS OF CHANGE: 20210712 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: HCW Biologics Inc. CENTRAL INDEX KEY: 0001828673 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825024477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: FWP SEC ACT: 1934 Act SEC FILE NUMBER: 333-256510 FILM NUMBER: 211085147 BUSINESS ADD
HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025 - The Globe and Mail Home Canada Business Investing Life Opinion World Politics Personal Finance Culture More More Latest in More Real Estate Sports Drive Watchlist For You Events Find clarity in the chaos. Subscribe now and save 70% Subscribe Digital access Digital + home delivery TSX 0.77 % S&P 500 0.5 % DOW 0.7 % NASDAQ 0.31 % Oil -3.23 % Dollar -0.16 % Gold 3.03 % tsx movers: CNQ-T -0.19 % CVE-T -0.8 % T-T + … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Subscribe Digital + Home Delivery Digital Access Globe2Go The New York Times Globe Email … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Jump to footer navigation © Copyright 2026 The Globe and Mail Inc. All rights reserved. 3
--> HCW Biologics- Characterization of a Fusion Protein Complex About Blog News & Events Knowledge Center Glossary & FAQs Case Studies About Blog News & Events Knowledge Center LinkedIn CONTACT US Characterization section Aggregation Charge Isoform Analysis Forced Degradation Studies Functional Testing HCP Analysis Liquid Chromatography (RP-HPLC, SEC, HIC, IEX) N and C Terminal Amino Acid Sequence Analysis Secondary, Tertiary and Higher Order Structure of Proteins section Amino Acid Analysis and Extinction Coefficient Disulfide Bridges Glycosylation and Carbohydrate Structur
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
HCW Biologics: HCWB Stock Price Quote & News | Robinhood Log In Sign Up Learn Blog Careers Help Log In Sign Up HCW Biologics 1D 1W 1M 3M YTD 1Y 5Y ALL Why Robinhood? Robinhood gives you the tools you need to put your money in motion. You can buy or sell HCW Biologics and other ETFs, options, and stocks. Sign up About HCWB HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade c … l HCW Biologics stocks, ETFs, and their options commission-free. Other fees may apply. See Robinhood Financial's fee schedule to learn more. Sign Up to Buy Watch HCWB
HCW Biologics Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 23 May 2026 HCW Biologics Inc. Public Company | 2018 | Florida, United States | 10-50 | NASDAQ: HCWB | www.hcwbiologics.com Public Company | 2018 | Florida, United States | 10-50 | NASDAQ: HCWB | www.hcwbiologics.com Last update 23 May 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Other Diseases Endocrinology and Metabolic Disease Fusion protein Biological products Monoclon … on rights agreement with the Investors, pursuant to which the Company agreed to submit to the U.S. Securities and Exchange Commission (the “SEC”) an initial registration statement on Form S-1 within 60 days of the closing date covering the resale of the purchased shares and underlying shares for warrants, which may be issued from time to time upon the exercise of such warrants, and to use commercially reasonable efforts to cause the registration statement to be declared effec … IND-Enabling studies in the second half of 2027 and intends to immediately IND application to evaluate HCW11-040 in patients at a high risk of developing BPD. BPD in neonates causes long-term health impacts primarily related to chronic lung disease, including reduced lung function, asthma-like symptoms, and higher susceptibility to infections, which can persist into adulthood. Survivors may also face neurodevelopmental delays, impaired exercise tolerance, and in severe cases … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
HCWB | Virtual Investor Virtual Investor | Access. Ideas. Clarity. Follow Follow Follow Featured Companies Events Series Contact Covered Companies: HCW Biologics Most Recent Event What This Means October 22, 2025 Dr. Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, discusses the Company’s lead product candidate, known as HCW11-040, which is the Company’s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor. HCW Biologics Inc. is a clinical-stage biopharmaceutical company dev
EX-10.6 6 d39345dex106.htm EX-10.6 EX-10.6 Exhibit 10.6 HCW Biologics Inc. 2929 North Commerce Parkway Miramar, Florida 33025 July 6, 2021 PERSONAL AND CONFIDENTIAL Peter Rhode [***] Re: Employment Agreement Dear Peter: It gives me great pleasure to offer you (the “Employee”) continued employment with HCW Biologics Inc. (the “Company”) in the position of Chief Scientific Officer and Vice President of Clinical Operations. As of the Effective Date (as defined below), this letter agreement (this “Agreement”) sets forth the terms and conditions that shall govern … ve within 60 days following Employee’s termination date (the “Release Deadline”). In addition, in no event will Severance Benefit be paid or provided until the Release actually becomes effective. If the termination of employment occurs at a time during the calendar year where the Release Deadline could occur in the calendar year following the calendar year in which Employee’s termination of employment occurs, then any severance payments or benefits under t … ake any severance payment provided for under this Section 4 on the Release Deadline. 5. Definitions . (a) For purposes of this Agreement, the term “Cause” shall mean any of the following: (a) Employee’s material breach of any agreement with the Company, including the Confidentiality Agreement, or any policy of the Company, which breach has not been cured within twenty (20) days following written notice to Employee thereof; (b) Employee’ … the remedies available to the Company by law, the Company shall be entitled to apply to a court of competent jurisdiction to obtain such equitable relief as may be permitted by law by such a court including injunctive relief from any violation or continuing violation by Employee of any term or provision of this Section 6. 7. Section 409(A) . (a) Notwithstanding anything to the contrary in this Agreement, no Severance Benefits to be paid or provided to Employee, if … pending the conclusion of any arbitration. This arbitration agreement does not apply to any claims that have been expressly excluded from arbitration by a governing law not preempted by the Federal Arbitration Act and does not restrict or preclude Employee from communicating with, filing an administrative charge or claim with, or providing testi
EX-10.5 2 hcwb-ex10_5.htm EX-10.5 EX-10.5   Exhibit 10.5   HCW BIOLOGICS INC. FIRST AMENDMENT TO AmendED AND RESTATED SENIOR SECURED NOTE PURCHASE AGREEMENT This First Amendment to Amended and Restated Senior Secured Note Purchase Agreement(this “ Amendment ”) is made as of September 30, 2024 (the “ Effective Date ”) by and between HCW Biologics Inc., a Delaware corporation (the “ Company ”), and each of the purchasers listed on Exhibit B attached thereto (each a “ Purchaser ” and together the “ Purchasers ”). RECI
HCW Biologics CEO buys shares and warrants | HCWB Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Ga
Empowered Patient Podcast: Extending Health Span with Focus on Chronic Inflammation Induced by Chemotherapy Used to Treat Age-Related Diseases with Dr. Hing Wong HCW Biologics Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies May 14, 2026 | 5 min read Twitter LinkedIn Facebook Email Print HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent … bling studies in the second half of 2027 and intends to immediately file an IND application to evaluate HCW11-040 in patients at a high risk of developing BPD. BPD in neonates causes long-term health impacts primarily related to chronic lung disease, including reduced lung function, asthma-like symptoms, and higher susceptibility to infections, which can persist into adulthood. Survivors may also face neurodevelopmental delays, impaired exercise tolerance, and in severe cases … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease | The Manila Times --> --> Sunday, June 14, 2026 Today's Paper HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease Sign In New user? Click Here Subscribe Sign In New user? Click Here OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS … red Ramsdell and Shimon Sakaguchi was recently acknowledged with the 2025 Nobel Prize in Physiology or Medicine for their groundbreaking work which was the discovery that Treg cells are the immune system’s security guards which prevent immune cells from attacking our own body. Get the latest news delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Pol
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Ge … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen May 27, 2026 | 5 min read Twitter LinkedIn Facebook Email Print Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW92 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCWB Stock Quote Price and Forecast | CNN CNN values your feedback 1. How relevant is this ad to you? 2. Did you encounter any technical issues? Video player was slow to load content Video content never loaded Ad froze or did not finish loading Video content did not start after ad Audio on ad was too loud Other issues Ad never loaded Ad prevented/slowed the page from loading Content moved around while ad loaded Ad was repetitive to ads I've seen previously Other issues Cancel Submit Thank You! Your effort and contribution in providing this feedback is much appreciated. Close Ad Feedback C
HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022 April 19, 2022 | 6 min read Twitter LinkedIn Facebook Email Print HCW Biologics Inc. announced that Hing C. Wong, Ph.D., Founder and CEO of HCW Bio … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
HCW Biologics (HCWB) Latest News & Stock Updates - Page 3 Skip to main Stocks Options ETFs Crypto Bonds High-Yield Cash Account API Agents More About Us Learn Support Sign In Get Started About HCWB Market cap P/E ratio Forecast Earnings News Pre-market After-hours HCWB • News Stocks HCW Biologics News HCWB Volume: 533.37K HCW Biologics (HCWB) Latest News & Updates Explore latest HCW Biologics (HCWB) News and Updates Stay updated on HCW Biologics (HCWB) with the latest news, market trends, and key developments to support informed investing decisions. Start investing in HCW Biologics (HC … during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Public’s Investing’s Fee Schedule to learn more. Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more. Investment Plans. Investment Plans (“Plans”) shown in our marketplace are for i